Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04333654 · ClinicalTrials.gov registry record · Phase 1
Hydroxychloroquine in Outpatient Adults With COVID-19
A Phase 1 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04333654: Clinical Trial Phase 1 study, sponsored by Sanofi.
NCT04333654 is a Phase 1 study that was terminated before completion, run by Sanofi. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04333654, a Phase 1 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Primary Objective: To assess the effect of hydroxychloroquine versus placebo on nasopharyngeal SARS-CoV-2 viral load in outpatient adults with COVID-19 Secondary Objectives: * To assess the effect of hydroxychloroquine versus placebo on clinical signs and symptoms and progression of disease in outpatient adults with COVID-19 * To assess the safety and tolerability of hydroxychloroquine in outpatient adults with COVID-19
Primary Outcome
Viral load assessed by PCR from a nasopharyngeal swab
Interventions
- DRUG Placebo
- DRUG Hydroxychloroquine SAR321068
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-04-12 |
| Est. Completion | 2020-05-26 |
| Phase | Phase 1 |
Why NCT04333654 stopped before completion
NCT04333654 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04333654 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04333654 about?
NCT04333654 is a clinical study titled "Hydroxychloroquine in Outpatient Adults With COVID-19". Primary Objective: To assess the effect of hydroxychloroquine versus placebo on nasopharyngeal SARS-CoV-2 viral load in outpatient adults with COVID-19 Secondary Objectives: * To assess the effect of hydroxychloroquine versus placebo on clinical signs and symptoms and progression of disease in ou...
What is the current status of trial NCT04333654?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-04-12. Estimated completion is 2020-05-26.
What interventions are being tested in trial NCT04333654?
The interventions under investigation include: Placebo (DRUG), Hydroxychloroquine SAR321068 (DRUG).
Who is sponsoring clinical trial NCT04333654?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04333654's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI